Purchase this article with an account.
T. Yoshida, K. Fujinami, K. Shinoda, Y. Miyake, M. T. Suzuki, K. Terao, Y. Yoshikawa, T. Iwata; Focal Macular Electroretinogram of Cynomolgus Monkey (Macaca fascicularis) With Early Onset Macular Degeneration. Invest. Ophthalmol. Vis. Sci. 2007;48(13):35.
Download citation file:
© ARVO (1962-2015); The Authors (2016-present)
To evaluate sensory retinal function of macula by focal macular electroretinogram on Cynomolgus monkey (Macaca fascicularis) pedigree with early onset macular degeneration.
The clinical fundus findings of pedigree with early onset macular degeneration (58 monkeys) were classified to 4 disease stage. Furthermore, the progression of the disease was confirmed based on previous records. To evaluate sensory retinal function of macula, focal macula electroretinograms(ERGs)was measured at 5, 10, and 15 degree angles around fovea for two individual monkeys at each stage of 0 to 3 under the fundus monitor during the recording.
Only few cases were traced back to over 7 years. However, significant deterioration of fundus within one year period was confirmed in 7 monkeys. In several monkeys drastic deterioration of fundus during 2 to 5 years after birth leading to dry-type AMD were observed. In these monkeys focal macula ERGs demonstrated the amplitudes around fovea were reduced and the oscillatory potentials were occasionally absent. Difference in amplitudes of focal macula ERGs between stage 3 monkeys and others became smaller as stimuli range was widen. These results suggest the accumulation of drusen tends to damage around fovea but not peripheral.
Focal macula ERGs was measured for Cynomolgus monkey pedigree with early onset macular degeneration. Affected monkeys showed deterioration of fundus findings by age in most cases. Deterioration of fundus findings of this monkey pedigree caused functional disorder of sensory retina specifically around fovea. These observations are similar to that of dry-type human AMD. This AMD monkey pedigree is potentially useful as animal model for AMD to test new therapies including anti- complement system drugs.
This PDF is available to Subscribers Only